Relay Therapeutics’ Dynamo platform combines machine learning and physics-based simulation to target dynamic protein conformations for oncology and genetic disease therapies. RLY-2608 targets ...

Relay Therapeutics' early clinical data for cancer drug RLY-2608 sparked investor concerns due to lack of robust evidence of efficacy, leading to a 40% stock decline. Despite investor skepticism, ...

Relay Therapeutics (RLAY) has received a new Buy rating, initiated by Bank of America Securities analyst, Jason Gerberry. Jason Gerberry has given his Buy rating due to a combination of factors that ...

Over the last decade, Australia has been the world’s dominant team in the women’s 400 freestyle relay, having won three consecutive Olympic titles and four of the last five world titles (three in a ...